Neurocrine Biosciences presented the first real-world head-to-head claims analysis comparing persistence for INGREZZA (valbenazine) versus AUSTEDO XR (deutetrabenazine) in adults with tardive dyskinesia. The update is supportive for INGREZZA's competitive positioning, but the article provides no numerical results or clear pricing/sales impact. The news is likely incremental rather than market-moving.
Neurocrine Biosciences presented the first real-world head-to-head claims analysis comparing persistence for INGREZZA (valbenazine) versus AUSTEDO XR (deutetrabenazine) in adults with tardive dyskinesia. The update is supportive for INGREZZA's competitive positioning, but the article provides no numerical results or clear pricing/sales impact. The news is likely incremental rather than market-moving.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
